Researchers at the University of California, San Diego School of
Medicine, with colleagues at the University of Rochester Medical Center,
have identified a new mechanism that appears to suppress tumor growth,
opening the possibility of developing a new class of anti-cancer drugs.
Writing in this week's online Early Edition of the Proceedings of the National Academy of Sciences (PNAS),
Willis X. Li, PhD, a professor in the Department of Medicine at UC San
Diego, reports that a particular form of a signaling protein called
STAT5A stabilizes the formation of heterochromatin (a form of
chromosomal DNA), which in turn suppresses the ability of cancer cells
to issue instructions to multiply and grow.
Specifically, Li and colleagues found that the unphosphorylated form
of STAT promotes and stabilizes heterochromatin, which keeps DNA tightly
packaged and inaccessible to transcription factors. "Therefore, genes
'buried' in heterochromatin are not expressed," explained Li.
Phosphorylation is a fundamental cellular function in which a
phosphate group is added to a protein or molecule, causing it to turn it
on or off or to alter its function. An unphosphorylated STAT lacks this
phosphate group.
Li said that in previous studies with fruit flies, the
unphosphorylated form of STAT caused chromatin to condense into
heterochromatin, while the phosphorylated version prompted dispersal and
loss of heterochromatin, furthering gene expression.
"Unphosphorylated STAT promotes and stabilizes heterochromatin
formation, which in turn suppresses gene transcription," said Li. "When
we expressed either HP1 (the central component of heterochromatin) or
unphosphorylated STAT5A in human cancer cells, many genes important for
cancer growth are suppressed. These cancer cells do not grow as fast or
big as their control parental cancer cells in mouse xenograft models."
Most of the known tumor suppressors, such as p53 or Rb, function by
inhibiting cell cycle progression or by spurring cell death, or
apoptosis. Li said their findings reveal a potential new way to inhibit
cancer gene expression, and may represent a new class of tumor
suppressors.
"We are in the process of identifying small molecule drugs that may
promote heterochromatin formation without stopping cell division or
causing cell death," he said. "These drugs, if found, may be effective
in treating cancers with fewer side effects."
Co-authors are Xiaoyu Hu, Amy Tsurumi and Hartmut Land, Department of
Biomedical Genetics, University of Rochester Medical Center;
Pranabananda Dutta, Jinghong Li and Jingtong Wang, Department of
Medicine, UCSD.
Funding for this research came, in part, from the National Institutes
of Health grants R01CA131326 and RO1CA138249 and a Leukemia &
Lymphoma Society Research Scholar grant
Journal Reference:
- Xiaoyu Hu, Pranabananda Dutta, Amy Tsurumi, Jinghong Li, Jingtong Wang, Hartmut Land, and Willis X. Li. Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth. PNAS, 2013 DOI: 10.1073/pnas.1221243110
Courtesy: ScienceDaily
No comments:
Post a Comment